This company has been marked as potentially delisted and may not be actively trading. NASDAQ:VBLT Vascular Biogenics (VBLT) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Vascular Biogenics Stock (NASDAQ:VBLT) 30 days 90 days 365 days Advanced Chart Get Vascular Biogenics alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.16▼$5.4652-Week Range N/AVolume161,505 shsAverage Volume2.19 million shsMarket Capitalization$423.91 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Vascular Biogenics Ltd., a biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. It develops VB-601 using monocyte targeting technology for various inflammatory indications. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel. Read More Receive VBLT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vascular Biogenics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VBLT Stock News HeadlinesMarket Unimpressed By VBL's 26% Jump In Net Profit, Shares Tank 5%July 30, 2024 | msn.comVBL Shares Climb As Q1 Profits Soar 25%: Why Analysts Think There's More To ComeMay 14, 2024 | msn.com$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold stocks — in past bull markets, these plays delivered gains as high as 5,000% to 9,800%, and Sean has now identified five companies he believes could see explosive moves in the early stages of what may be the biggest gold rally yet. | Weiss Ratings (Ad)Vascular Biogenics (VBLT) Price Target Increased by 160.00% to 13.26November 2, 2023 | msn.comNotable Labs Closes Merger Transaction With VBL TherapeuticsOctober 16, 2023 | finance.yahoo.comVBL Therapeutics Announces Results of Annual and Special Shareholder MeetingOctober 12, 2023 | finance.yahoo.comVBL Therapeutics Reminds Shareholders to Vote in the Upcoming Annual and Special Shareholder MeetingOctober 4, 2023 | finance.yahoo.comVascular Biogenics Rises on Presentation HypeSeptember 9, 2023 | finance.yahoo.comSee More Headlines VBLT Stock Analysis - Frequently Asked Questions How were Vascular Biogenics' earnings last quarter? Vascular Biogenics Ltd. (NASDAQ:VBLT) announced its quarterly earnings results on Monday, November, 15th. The biopharmaceutical company reported ($0.09) EPS for the quarter, beating analysts' consensus estimates of ($0.11) by $0.02. The biopharmaceutical company had revenue of $0.20 million for the quarter, compared to the consensus estimate of $0.20 million. What other stocks do shareholders of Vascular Biogenics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vascular Biogenics investors own include T2 Biosystems (TTOO), SCYNEXIS (SCYX), Onconova Therapeutics (ONTX), OPKO Health (OPK), VBI Vaccines (VBIV), TherapeuticsMD (TXMD) and Vaxart (VXRT). Company Calendar Last Earnings11/15/2021Today9/15/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:VBLT Previous SymbolNASDAQ:VBLX CIK1603207 Webwww.vblrx.com Phone(728) 993-5000Fax972-8993-5001Employees7Year Founded2000Profitability EPS (Trailing Twelve Months)($0.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$32.30 million Net MarginsN/A Pretax Margin-3,317.05% Return on Equity-73.45% Return on Assets-54.11% Debt Debt-to-Equity RatioN/A Current Ratio4.63 Quick Ratio4.63 Sales & Book Value Annual Sales$660 thousand Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.32 per share Price / BookN/AMiscellaneous Outstanding Shares77,640,000Free Float72,881,000Market Cap$423.91 million OptionableOptionable Beta0.77 Social Links Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:VBLT) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersNew Biotech Backed by Proven Incubator Now Open to PublicA successful biotech incubator just opened its next chapter - and you're invited to their raise. This deal ...i2i Marketing Group, LLC | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis Coin Could Explode, and it’s Hiding in Plain Sight!The #1 coin with skyrocket potential right now... Sometimes the biggest opportunities are hiding in plain s...Crypto 101 Media | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredDalio’s $319 Million Gold BetA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored“Godfather of AI’s” dire warningAI pioneer Geoffrey Hinton warns the technology could create massive unemployment and widen inequality, but Po...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vascular Biogenics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vascular Biogenics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
